Oncology, Orphans Dominate Japan Fiscal 2018 Approvals
Oncology again dominated new drug approvals in Japan last fiscal year, when expedited and special review pathways also played a major role in ensuring early access to new therapies.
Oncology again dominated new drug approvals in Japan last fiscal year, when expedited and special review pathways also played a major role in ensuring early access to new therapies.